Tejaswini Kulkarni
, Interstitial Lung Disease Program Director · University of Alabama Hospital
Credentials: · · · · · · ·
History
PresentInterstitial Lung Disease · University of Alabama Hospital
- 2012–2015
Pulmonary Disease and Critical Care Medicine
- 2009–2012
Internal Medicine
Research
Citrullinated vimentin mediates development and progression of lung fibrosis
Science Translational Medicine · 2021 · 107 citations
Matrix Remodeling in Pulmonary Fibrosis and Emphysema
Review · American Journal of Respiratory Cell and Molecular Biology · 2016 · First of 5 authors · 102 citations
American Journal of Respiratory and Critical Care Medicine · 2019 · 96 citations
13 papers · 8 as a fellow
12 papers
8 papers
Tracy Luckhardt
8 papers
8 papers · 4 as a fellow
7 papers · 3 as a resident
6 papers
5 papers
Clinical trials
- 2026–2027
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Site PI · Recruiting · Phase 2
Rein Therapeutics
- 2025–2031
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Site PI · Recruiting · Phase 2
Avalyn Pharma Inc.
- 2023–2027
Site PI · Recruiting · Phase 3
United Therapeutics
- 2014–2031
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Site PI · Recruiting
Duke University